Search results for "prednisone"

showing 10 items of 98 documents

Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports

2017

Abstract Rationale: To report our experience on 7 patients (4 males and 3 females), affected by nonparaneoplastic Lambert–Eaton myasthenic syndrome, treated with 3,4-diaminopyridine phosphate (3,4-DAPP) either alone or in combination with other immunosuppressants or steroids. Patient concerns: Patients have been evaluated at specific timepoints (ie, baseline and last 5 year follow-up), with neurological examination, autoantibodies against presynaptic voltage-gated Cav2.1 (P/Q type) calcium ion channel (VGCC) dosage, neurophysiological evaluation focusing on the increased amplitude of the compound muscle action potential (cMAP) after maximum voluntary effort, quantitative myasthenia gravis (…

AdultMalemedicine.medical_specialtyAzathioprineNeurological examination030204 cardiovascular system & hematologySeverity of Illness Index5300nonparaneoplastic-Lambert–Eaton myasthenic syndrome03 medical and health sciences0302 clinical medicinePrednisoneInternal medicineSeverity of illnessActivities of Daily LivingAzathioprinemedicineHumansMuscle StrengthClinical Case Report4-AminopyridineAdverse effect34-diaminopyridine phosphate; nonparaneoplastic-Lambert-Eaton myasthenic syndrome; 4-Aminopyridine; Activities of Daily Living; Adult; Azathioprine; Drug Therapy Combination; Female; Humans; Immunosuppressive Agents; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscle Strength; Prednisone; Severity of Illness Index; Treatment Outcome; Medicine (all)medicine.diagnostic_testbusiness.industry34-diaminopyridine phosphateGeneral MedicineMiddle Agedmedicine.diseaseMyasthenia gravisLambert-Eaton Myasthenic SyndromeTreatment OutcomeConcomitantPrednisoneDrug Therapy CombinationFemaleAmifampridinebusinessLambert-Eaton myasthenic syndrome030217 neurology & neurosurgeryImmunosuppressive Agentsmedicine.drugResearch Article
researchProduct

Cognitive impairment in Behçet's disease patients without overt neurological involvement

2003

We investigated the prevalence of cognitive impairment in patients with Behc¸et’s disease (BD) without overt neurological involvement. The influence of disease duration, disease activity, prednisone dosage, and anxiety and depression levels was evaluated. Twenty-six consecutive BD outpatients and 26 healthy controls matched for age, education and sex completed a comprehensive neuropsychological battery including tests of memory, visuospatial and constructional abilities, language, attention and psychomotor speed, non-verbal reasoning and executive functioning. The Hamilton scales for anxiety and depression were administered. Disease activity was assessed using the Behc¸et’s Disease Current …

AdultMalemedicine.medical_specialtyBehcet's diseaseNeuropsychological TestsNeuropsychologyPredictive Value of TestsPrednisoneInternal medicineOdds RatiomedicineCorticosteroidHumansAttentionDisease activityDepression (differential diagnoses)DemographyLanguagePsychiatric Status Rating ScalesPsychomotor learningVascular diseaseBehcet SyndromeCase-control studyNeuropsychologyVerbal Learningmedicine.diseaseCognitive impairmentMemory Short-TermNeurologyCase-Control StudiesPhysical therapyAnxietySettore MED/26 - NeurologiaFemaleNeurology (clinical)medicine.symptomCognition DisordersPsychologyBehcet’s diseasePsychomotor Performancemedicine.drugJournal of the Neurological Sciences
researchProduct

Mycophenolate is effective in the treatment of pemphigus vulgaris.

1999

Background Pemphigus vulgaris is a potentially life-threatening autoimmune disease. Although combination therapies with prednisone and azathioprine are usually effective in controlling the disease, some patients either do not respond to this treatment or show early relapses. Objective To find out whether mycophenolate mofetil would be an effective drug in controlling pemphigus vulgaris in patients who failed initial treatment with azathioprine and prednisone. Results Twelve patients who were initially diagnosed as having pemphigus vulgaris and had relapsed while undergoing treatment with azathioprine (1.5-2 mg/kg of body weight) and prednisolone (2 mg/kg of body weight) subsequently receive…

AdultMalemedicine.medical_specialtyCombination therapymedicine.medical_treatmentPrednisoloneAzathioprineDermatologyMycophenolic acidPrednisoneAzathioprineMedicineHumansChemotherapybusiness.industryPemphigus vulgarisGeneral MedicineMiddle AgedMycophenolic Acidmedicine.diseaseDermatologyPemphigusTreatment OutcomeChemotherapy AdjuvantPrednisoloneDrug Therapy CombinationFemalebusinessImmunosuppressive AgentsPemphigusmedicine.drugArchives of dermatology
researchProduct

Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study.

1986

Forty patients with Graves' ophthalmopathy stages III-V were divided into two groups in a random manner according to their year of birth. Group I received prednisone in decreasing dosage. Group II received prednisone at a comparable dosage and ciclosporin. Steroids were discontinued after 10 weeks in the two groups. In the patients of group II, ciclosporin was continued over 12 months. The therapeutic effect was assessed by an activity score based on subjective and objective symptoms (computerized tomography and sonography of the orbit, Hertel values, clinical findings). All signs of endocrine ophthalmopathy improved significantly in both groups (P less than 0.01 in group I; P less than 0.0…

AdultMalemedicine.medical_specialtyEye DiseasesClinical BiochemistryVisual AcuityCyclosporinsBiochemistryGastroenterologylaw.inventionGraves' ophthalmopathyPharmacotherapyRandomized controlled triallawPrednisoneInternal medicinemedicineHumansProspective StudiesProspective cohort studyClinical Trials as TopicDose-Response Relationship Drugbusiness.industryTherapeutic effectGeneral MedicineMiddle AgedCiclosporinmedicine.diseaseGraves DiseaseClinical trialEndocrinologyPrednisoneDrug Therapy CombinationFemalebusinessmedicine.drugFollow-Up StudiesEuropean journal of clinical investigation
researchProduct

Urinary glycosaminoglycans in Graves' ophthalmopathy.

1990

An increased accumulation of glycosaminoglycans (GAG) in retrobulbar tissues has been reported in patients with thyroid eye disease. We examined the quantitative urinary GAG excretion in 101 patients with Graves' ophthalmopathy of different classes, 36 patients with Graves' hyperthyroidism without ophthalmopathy, 14 patients with toxic nodular goitre and 103 control subjects. Glycosaminoglycans were isolated from 24-h urine collections by precipitation with cetylpyridinium chloride and ethanol followed by photometrical quantification of hexuronic acids after reaction with carbazole. In comparison with the control group (15.8, 10.4, 21.6 mg/24 h; median, 25th, 75th percentile) a significant …

AdultMalemedicine.medical_specialtyGoiterAdolescentEndocrinology Diabetes and MetabolismGraves' diseaseUrinary systemUrineGraves' ophthalmopathyExcretionEndocrinologyInternal medicineImmunopathologymedicineHumansAgedGlycosaminoglycansAged 80 and overbusiness.industryThyroidMiddle Agedmedicine.diseaseCombined Modality TherapyGraves DiseaseEndocrinologymedicine.anatomical_structurePrednisoneFemalebusinessGoiter NodularClinical endocrinology
researchProduct

Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial.

2011

Abstract Background Steroids, the mainstay of Crohn's disease treatment, have been associated with systemic side effects. Aim To evaluate the efficacy and tolerability of beclomethasone dipropionate for maintaining remission induced by a short course of systemic steroids in patients with Crohn's ileitis with or without right colonic involvement. Methods Patients (n = 84) with active Crohn's disease who achieved remission during a 2-week prednisone run-in period were randomised to receive beclomethasone dipropionate for 24 weeks or continue prednisone for a further 2 weeks followed by placebo for 22 weeks. The primary outcome was relapse rate (Crohn's Disease Activity Index score > 150 and a…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaRemissionKaplan-Meier EstimateBeclomethasone dipropionate Crohn's disease RemissionPlaceboGastroenterologyDrug Administration ScheduleMedication Adherencelaw.inventionDouble blindCrohn DiseaseDouble-Blind MethodRandomized controlled triallawPrednisoneInternal medicineSecondary PreventionmedicineHumansIleitisAdverse effectGlucocorticoidsAgedCrohn's diseaseHepatologybusiness.industryRemission InductionBeclomethasoneGastroenterologyBeclomethasone dipropionate Crohn's ileitis:.Middle Agedmedicine.diseaseSurgeryBeclomethasone dipropionateCrohn's diseaseTreatment OutcomeTolerabilityPrednisoneFemaleTablets Enteric-Coatedbusinessmedicine.drug
researchProduct

Tubulointerstitielle-Nephritis-Uveitis-Syndrom (TINU-Syndrom)

1995

Abstract For 10 weeks a 25-year-old man had been suffering from tiredness, fatigue, nausea and a 16 kg weight loss. Erythrocyte sedimentation rate (83/133 mm), serum C-reactive protein (5.5 mg/dl) and creatinine (5.05 mg/dl) were all elevated. He also had proteinuria (1120 mg daily), sterile leukocytosis and a creatinine clearance of 10 ml/min. Renal biopsy showed interstitial nephritis and bone marrow biopsy revealed non-caseous epithelioid-cell granulomas. 14 days after admission he developed acute iritis in the right eye. Other causes having been excluded, the diagnosis of tubulo-intestinal nephritis with uveitis (TINU syndrome) was made. The clinical symptoms and laboratory findings imp…

AdultMalemedicine.medical_specialtyTime FactorsBiopsyInterstitial nephritisIritisRenal functionKidneyKidney Function TestsGastroenterologyDiagnosis DifferentialUveitischemistry.chemical_compoundPrednisoneInternal medicineHumansMedicineLeukocytosisCreatininemedicine.diagnostic_testbusiness.industrySyndromeGeneral Medicinemedicine.diseaseEndocrinologychemistryErythrocyte sedimentation rateAcute DiseaseNephritis InterstitialPrednisoneRenal biopsymedicine.symptombusinessNephritismedicine.drugDMW - Deutsche Medizinische Wochenschrift
researchProduct

Burkitt lymphoma associated with human immunodeficiency virus infection and pulmonary tuberculosis: A case report.

2019

Abstract Introduction: The association of human immunodeficiency virus (HIV) infection with Burkitt lymphoma is related to the presence of Epstein Barr virus infection and the impact of the HIV antigen on the expansion of B-polyclonal cells. In Southeast Europe, the association is rare, and recognizing this is important in the therapeutic decision to increase patient survival rate. The association of HIV with Burkitt lymphoma and tuberculosis is even more rarely described in the literature. Patient concerns: We present the case of a 40-year-old patient who presented with a 3-week history of fever (max. 38.7 °C), painful axillary swelling on the right side, lumbar pain, gait disorders, heada…

AdultMalemedicine.medical_specialtyTuberculosisAntitubercular AgentsAntineoplastic AgentsHIV Infectionshuman immunodeficiency virus infectionNeurosurgical ProceduresMycobacterium tuberculosis03 medical and health sciences0302 clinical medicinePharmacotherapyFatal Outcomeimmune system diseasesInternal medicinehemic and lymphatic diseasesAntiretroviral Therapy Highly ActivemedicineHumans030212 general & internal medicineClinical Case ReportEpstein–Barr virus infectionTuberculosis PulmonaryImmunodeficiencydose-adjusted etoposide doxorubicin and cyclophosphamide with vincristine prednisone and rituximabbiologyClinical Deteriorationbusiness.industry4900BrainBurkitt lymphomaGeneral MedicineViral Loadhighly active antiretroviral therapymedicine.diseasebiology.organism_classificationDecompression SurgicalLymphomaCD4 Lymphocyte CountSpinal Cord030220 oncology & carcinogenesisSputummedicine.symptombusinessViral loadpulmonary tuberculosisResearch ArticleMedicine
researchProduct

Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study.

2011

The aim of this study was to verify the efficacy and the safety of transtympanic dexamethasone to treat sudden sensorineural hearing loss as first and single drug method. Considering ethical implication of performing a mininvasive procedure on middle ear, we matched such proposed treatment with systemic prednisone administration that represents the widest adopted protocol. Randomized prospective study was conducted. The inclusion criterion was a sudden sensorineural hearing loss of at least 30 dB across three contiguous frequencies over a period of 24 h. Group A received transtympanic steroid injections; Group B received oral administration of steroids. 25 patients were treated with transty…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing Loss SensorineuralAdministration OralInjections IntralesionalRisk AssessmentSeverity of Illness IndexDexamethasoneDrug Administration ScheduleAudiometryOral administrationPrednisoneSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyDexamethasoneAgedAnalysis of Variancemedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryGeneral MedicineHearing Loss SuddenMiddle AgedSurgeryCochlea Deafness Round window Sudden sensorineural hearing loss Steroid TranstympanicTreatment OutcomeOtorhinolaryngologyOtorhinolaryngologyFemaleNeurosurgeryAudiometrybusinessmedicine.drugFollow-Up Studies
researchProduct

MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.

1990

Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group wi…

AdultMalemedicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentLeucovorinSalvage therapyGastroenterologyBleomycinimmune system diseaseshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIntermediate GradeCyclophosphamideAgedChemotherapybusiness.industryLymphoma Non-HodgkinHematologyGeneral MedicineMiddle Agedmedicine.diseaseNon-Hodgkin's lymphomaSurgeryLymphomaMethotrexateDoxorubicinVincristinePrednisoneFemaleNeoplasm Recurrence LocalbusinessProgressive diseasemedicine.drugBlut
researchProduct